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Geographic Barriers to Comprehensive, Coordinated HIV Care in the US South
Kimmel AD, et al. 
Virginia Commonwealth University School of Medicine, Department of Health Behavior and Policy
Awareness of HIV status is critical for achieving UNAIDS targets, particularlysub-populations at high risk of acquiring and transmitting HIV who mayrequire targeted, resource-intensive strategies for HIV test uptake.Long distance truck drivers (LDTDs) are a high-HIV-risk sub-populationfacing unique healthcare barriers due to continuous travel and irregularschedules. A novel intervention—the choice to HIV self-test (CHIVST) at aroadside clinic—increased test uptake for Kenyan LDTDs (Kelvin AIDS Care2018). We conducted a trial-based cost-effectiveness analysis of CHIVST vsprovider testing to inform decision making in resource-limited settings.
HIV testing in long-distance truck drivers
Effectiveness data came from a randomized controlled trial of clinic- orhome-based self-administered oral HIV testing (n=150) vs provider-administered testing (standard of care, n=155) for LDTDs at roadside clinicsin Kenya. Economic cost data were from the literature, reflected a societalperspective, and were reported in 2017 international dollars (2017 I$).Generalized Poisson and linear gamma regression models were used toestimate effectiveness and incremental costs. Incremental effectiveness wasthe reciprocal of the difference in absolute risk of HIV testing uptake acrosstrial arms and expressed as the number needed to treat, or the numberoffered CHIVST for an additional HIV test uptake. We reported incrementalcost-effectiveness ratios, with 95% CIs calculated using Fieller’s theorem.Deterministic sensitivity analysis identified key cost drivers of variation inthe cost-effectiveness ratio. Non-parametric bootstrapping was used toestimate the probability of cost-effectiveness at a given willingness-to-paythreshold.
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Offering the choice of HIV self-testing to long-distance truck drivers at
roadside clinics is a highly efficient use of resources. Our findings add togrowing evidence on the cost-effectiveness of HIV self-testing among high-risk populations in resource-limited settings. Future work should considerlong-term health and economic outcomes, which were not captured in thisstudy’s analytic time horizon, as well as the application of self-testing optionsin other high-risk populations.
Choice of self-testing is an efficient use of resources
Table	1.	Mean	per	patient	costs	for	CHIVST	vs	standard	of	care	(2017	I$)
Cost	domain
Mean	per	patient	costs	[95%	CI]	
CHIVST SOC P-valueHIV	test	kit 13.17		[11.52	– 14.81]	 0.00			[0.00	– 0.00]	 <0.001	Medical	supplies 0.28				[0.26	– 0.31]	 0.25			[0.23	– 0.28]	 0.090	Labor	Nurses 2.60				[2.43	– 2.78]	 1.87			[1.68	– 2.06]	 <0.001	Other	 0.94				[0.87	– 1.02]	 0.84			[0.76	– 0.93]	 0.090	Health	facility 1.57				[1.44	– 1.71]	 1.41			[1.27	– 1.55]	 0.090	Equipment 0.11				[0.43	– 0.17]	 0.00			[0.00	– 0.00]	 <0.001	Overhead 4.07				[3.79	– 4.35]	 3.47			[3.12	– 3.82]	 0.009	Patient	time 3.79				[3.55	– 4.04]	 2.62			[2.35	– 2.88]	 <0.001	
Per	patient	cost 26.56		[24.31	– 28.80]	 10.47	[9.43– 11.52]	 <0.001	
Figure	2.	The	probability	CHIST	is		cost-effective	is	high	at	low	WTP	thresholds
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Offering	self-administered	oral	HIV-testing	is	a	cost-
effective strategy	to	increase	HIV	test	uptake	for	long-distance	truck	drivers
Table	2.	Incremental	effectiveness,	costs,	and	cost-effectiveness
Outcome Base	case	estimate 95%	CINumber	needed	to	treat	(NNT) 6.25 [5.00	– 8.33]Incremental	cost	(2017	I$) 15.55 [12.72	– 18.38]Cost-effectiveness	ratio	(2017	I$) 97.18 [65.74	– 120.98]
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Figure	1.	Cost	of HIV	self-test	kit	is	the	primary	driver	of	variation	in	the	ICER
Estimating cost-effectiveness
LDTDs offered CHIVST were 23% (95% CI 11 – 37%) more likely to uptake anyHIV test vs those offered provider-administered testing. This translated to oversix LDTDs offered CHIVST for each additional test uptake (Table 2).
CHIVST is cost-effective at willingness to pay threshold of I$97 for each
additional test uptake. This cost-effectiveness ratio falls below 3x Kenya’s2017 GDP/capita ((I$97 < I$9,774, Table 2), a commonly used willingness topay threshold for assessing cost-effectiveness in low-income settings. Perpatient costs across cost domains ranged from I$0.11 (equipment) to I$13.17(HIV self-test kit), with mean total per patient costs for CHIVST >2x for SOC(Table 1).
Choice of self-testing: Costs more, but cost-effective
Self-test kits and patient time are the main cost drivers of cost-effectiveness(Figure 1). The probability that CHIVST is cost-effective approaches one at awillingness-to-pay threshold of I$140 (Figure 2), which is substantially lowerthan the GDP/capita of Kenya in 2017.
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